FDA warned USV Private Limited that its sterile injectable manufacturing in Daman, India, had aseptic-processing, facility-design and visible-particulate violations.
What happened
FDA inspected USV's drug manufacturing facility in Dabhel, Daman, India, from April 7 to 17, 2026. The agency found aseptic processing and facility/equipment design problems that risked contamination of sterile injectables, plus an inadequate visual inspection program for visible particulates. FDA reviewed USV's May 8, 2026, response to the Form FDA 483 (inspection observations) and found it inadequate.
What FDA found
USV lacked adequate aseptic-processing procedures and controls; smoke studies showed swirling or upward airflow rather than unidirectional flow, and operators breached first air during interventions, risking sterility.
21 CFR 211.113(b)The facility and equipment design did not adequately protect sterile drugs; a conveyor blocked ISO 5 airflow and critical aseptic areas could not maintain ISO 5 conditions.
21 CFR 211.42(c) and 21 CFR 211.63USV's visual inspection program for injectables lacked action limits for visible particulates, did not classify particles as extrinsic or intrinsic, and failed to investigate atypical trends.
21 CFR 211.160(b)USV released some batches without adequate visible-particulate assessment before March 28, 2026.
21 CFR 211.160(b)FDA found USV's quality systems inadequate and said the quality unit was not enabled to exercise proper authority or had not sufficiently implemented its responsibilities.
What FDA wants
FDA asks USV to promptly address the violations and provide comprehensive CAPA plans, independent risk assessments and airflow/visual-inspection remediation, plus a qualified consultant's six-system audit before seeking resolution of its compliance status. It also asks USV to clarify whether it will resume U.S. manufacturing and to notify FDA before resuming; no response deadline is stated in the letter.
Who should pay attention
- Sterile injectable manufacturers and aseptic fill-finish operations
- Companies buying or distributing USV's sterile injectables
- Quality teams responsible for visual inspection and contamination control
This is a summary. Read the original letter on fda.gov.